Table 4

Multivariate analysis: effect on recurrence of acid suppressants taken at any time during phase 3 studies (mITT inpatients, n=701)

			95% CI
Variable	Comparison	Adjusted OR	Lower	Upper	p Value
PPI
Age category	10-year increase in age	1.137	0.971	1.332	0.1098
Serum albumin	<2.5 vs ≥2.5 g/dL	0.992	0.604	1.629	0.9738
Serum creatinine	≥1.5 vs <1.5 mg/dL	1.657	0.948	2.896	0.0761
WCC	≥15×10⁹ vs <15×10⁹/L	0.998	0.560	1.778	0.9951
Treatment	Fidaxomicin vs vancomycin	0.488	0.306	0.778	0.0026
PPI use	Yes vs no	1.539	0.953	2.484	0.0781
H2RA
Age category	10-year increase in age	1.138	0.973	1.332	0.1064
Serum albumin	<2.5 vs ≥2.5 g/dL	1.021	0.621	1.677	0.9351
Serum creatinine	≥1.5 vs <1.5 mg/dL	1.776	1.018	3.101	0.0432
WCC	≥15×10⁹ vs <15×10⁹/L	0.954	0.536	1.697	0.8719
Treatment	Fidaxomicin vs vancomycin	0.506	0.318	0.804	0.0039
H2RA use	Yes vs no	0.493	0.202	1.202	0.1199
PPI and/or H2RA
Age category	10-year increase in age	1.141	0.975	1.335	0.1007
Serum albumin	<2.5 vs ≥2.5 g/dL	0.995	0.606	1.636	0.9856
Serum creatinine	≥1.5 vs <1.5 mg/dL	1.688	0.967	2.948	0.0654
WCC	≥15×10⁹ vs <15×10⁹/L	1.004	0.563	1.791	0.9879
Treatment	Fidaxomicin vs vancomycin	0.498	0.313	0.793	0.0033
PPI/H2RA use	Yes vs no	1.353	0.828	2.212	0.2275

H2RA, histamine-2 receptor antagonist; mITT, modified intent to treat; PPI, proton pump inhibitor; WCC, white cell count.